CD19 +
About
Biomarker Type: Protein expression
Present: True
Marker: CD19
Unit: status
Equality: =
Value: Positive
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| Sensitivity (+) | BCR::ABL1, CD19 + | Acute Lymphoid Leukemia | Blinatumomab |